Cited 20 times in
Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 송선옥 | - |
dc.contributor.author | 윤유정 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이영기 | - |
dc.contributor.author | 이현철 | - |
dc.contributor.author | 조용인 | - |
dc.contributor.author | 차봉수 | - |
dc.contributor.author | 김광준 | - |
dc.date.accessioned | 2014-12-18T09:48:41Z | - |
dc.date.available | 2014-12-18T09:48:41Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 2233-6079 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88874 | - |
dc.description.abstract | BACKGROUND: This study compared the glycemic effectiveness of three metformin-based dual therapies according to baseline hemoglobin A1c (HbA1c) to evaluate the appropriateness of the guideline enforced by the National Health Insurance Corporation of Korea for initial medication of type 2 diabetes (T2D). METHODS: This prospective observational study was conducted across 24 weeks for drug-naïve Korean T2D patients with HbA1c greater than 7.5%. Subjects were first divided into three groups based on the agent combined with metformin (group 1, gliclazide-modified release or glimepiride; group 2, pioglitazone; group 3, sitagliptin). Subjects were also classified into three categories according to baseline HbA1c (category I, 7.5%≤HbA1c<9.0%; category II, 9.0%≤HbA1c<11.0%; category III, 11.0%≤HbA1c). RESULTS: Among 116 subjects, 99 subjects completed the study, with 88 subjects maintaining the initial medication. While each of the metformin-based dual therapies showed a significant decrease in HbA1c (group 1, 8.9% to 6.4%; group 2, 9.0% to 6.6%; group 3, 9.3% to 6.3%; P<0.001 for each), there was no significant difference in the magnitude of HbA1c change among the groups. While the three HbA1c categories showed significantly different baseline HbA1c levels (8.2% vs. 9.9% vs. 11.9%; P<0.001), endpoint HbA1c was not different (6.4% vs. 6.6% vs. 6.0%; P=0.051). CONCLUSION: The three dual therapies using a combination of metformin and either sulfonylurea, pioglitazone, or sitagliptin showed similar glycemic effectiveness among drug-naïve Korean T2D patients. In addition, these regimens were similarly effective across a wide range of baseline HbA1c levels. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | DIABETES & METABOLISM JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naïve Korean Type 2 Diabetic Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Young Ki Lee | - |
dc.contributor.googleauthor | Sun Ok Song | - |
dc.contributor.googleauthor | Kwang Joon Kim | - |
dc.contributor.googleauthor | Yongin Cho | - |
dc.contributor.googleauthor | Younjeong Choi | - |
dc.contributor.googleauthor | Yujung Yun | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Eun-Seok Kang | - |
dc.contributor.googleauthor | Bong Soo Cha | - |
dc.contributor.googleauthor | Hyun Chul Lee | - |
dc.identifier.doi | 10.4093/dmj.2013.37.6.465 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A02029 | - |
dc.contributor.localId | A02586 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A02953 | - |
dc.contributor.localId | A03301 | - |
dc.contributor.localId | A03866 | - |
dc.contributor.localId | A03996 | - |
dc.contributor.localId | A00317 | - |
dc.relation.journalcode | J00720 | - |
dc.identifier.eissn | 2233-6087 | - |
dc.identifier.pmid | 24404518 | - |
dc.subject.keyword | Diabetes mellitus, type 2 | - |
dc.subject.keyword | Metformin | - |
dc.subject.keyword | Pioglitazone | - |
dc.subject.keyword | Sitagliptin | - |
dc.subject.keyword | Sulphonylurea | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.alternativeName | Song, Sun Ok | - |
dc.contributor.alternativeName | Yun, Yu Jung | - |
dc.contributor.alternativeName | Lee, Byung Wan | - |
dc.contributor.alternativeName | Lee, Young Ki | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.alternativeName | Cho, Yong In | - |
dc.contributor.alternativeName | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | Song, Sun Ok | - |
dc.contributor.affiliatedAuthor | Yun, Yu Jung | - |
dc.contributor.affiliatedAuthor | Lee, Byung Wan | - |
dc.contributor.affiliatedAuthor | Lee, Young Ki | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Cho, Yong In | - |
dc.contributor.affiliatedAuthor | Cha, Bong Soo | - |
dc.contributor.affiliatedAuthor | Kim, Kwang Joon | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 37 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 465 | - |
dc.citation.endPage | 474 | - |
dc.identifier.bibliographicCitation | DIABETES & METABOLISM JOURNAL, Vol.37(6) : 465-474, 2013 | - |
dc.identifier.rimsid | 33683 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.